Beijing Cancer Hospital
Beijing, Beijing Municipality, China
171 recruiting
Showing 1–20 of 263 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeOne Medicines780 enrolled277 locationsNCT05100862
Recruiting
Phase 2
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
Non-small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd86 enrolled17 locationsNCT07164170
Recruiting
Phase 1
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.36 enrolled4 locationsNCT06992713
Recruiting
Phase 1Phase 2
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Advanced Solid Tumor
BioNTech SE375 enrolled17 locationsNCT07147348
Recruiting
Phase 3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
iO Resistant sqNSCLC
Takeda600 enrolled44 locationsNCT07217301
Recruiting
Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche100 enrolled62 locationsNCT05862285
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled295 locationsNCT06926868
Recruiting
Phase 3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Boehringer Ingelheim670 enrolled236 locationsNCT07472517
Recruiting
Phase 2Phase 3
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
GIST - Gastrointestinal Stromal TumorAdvanced
Ningbo Newbay Technology Development Co., Ltd255 enrolled32 locationsNCT07379047
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled136 locationsNCT07225946
Recruiting
Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled186 locationsNCT07276399
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748
Recruiting
Phase 3
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.438 enrolled1 locationNCT07518147
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Early Phase 1
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
Relapsed/Refractory Large B-Cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.12 enrolled6 locationsNCT07606937
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651